Bluefin Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bluefin Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-54,800	Closed	-$16K	–	399
2020 Q1	$16K	Sell	54,800 -69,700	-56%	-$6.01M	﹤0.01%	366
2019 Q4	$296K	Buy	+124,500	New	+$9.4M	0.02%	347
2016 Q1	–	Sell	-21,200	Closed	-$6K	–	492
2015 Q4	$6K	Hold	21,200	–	–	﹤0.01%	596
2015 Q3	$88K	Buy	+21,200	New	+$2.83M	0.01%	386
2015 Q1	–	Sell	-44,400	Closed	-$1.16M	–	439
2014 Q4	$1.16M	Sell	44,400 -50,600	-53%	-$4.21M	0.07%	231
2014 Q3	$759K	Buy	+95,000	New	+$6.24M	0.04%	341

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bluefin Capital Management's BMRN Position: Q3 2019 in Review

Bluefin Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 8,400 shares — an estimated $719K sold.

Bluefin Capital Management first reported a position in BMRN in Q2 2015 and held it in 2 quarters. The position peaked at $1.67M in Q2 2015. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Bluefin Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Bluefin Capital Management sold 8,400 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $719K.
Bluefin Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 2 quarters.
Bluefin Capital Management's BioMarin Pharmaceuticals position peaked at $1.67M in Q2 2015.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Bluefin Capital Management's 13F filing for Q3 2019, filed 15 Nov 2019.